Effect of front-line therapy with fludarabine, cytarabine, filgrastim, and gemtuzumab ozogamicin (FLAG-GO) on outcome in core-binding factor associated acute myelogenous leukemia (CBF-AML).

6552 Background: To compare survival outcomes among patients (pts) with CBF-AML treated with a regimen of fludarabine, cytarabine, filgrastim, and GO (FLAG-GO) or with idarubicin, cytarabine ± filgrastim (IA/IAG) regimen. Methods: Outcomes of pts with previously untreated CBF-AML enrolled in sequential clinical protocols at M. D. Anderson Cancer Center were reviewed and survival outcomes were compared in a fitted multivariate Cox model. Results: Between 1999 and 2009, 153 pts with CBF-AML [Inversion 16=84 (55%), t (8;21) = 69 (45%)] were enrolled on front-line protocols. Median age was 43 yrs, range (16-83 yrs) and median overall survival (OS) was 12.5 years [95% confidence interval (CI) of 5.2 years; not reached]. Sixty-eight pts (44%) died or relapsed (event). The median time to event was 5.2 years (95% CI of 1.6 years; not reached). Forty-seven (31%) pts were treated with IA/IAG and 39 pts (25%) were treated with FLAG-GO. The induction/consolidation regimens are summarized in the Table. On multivariate...